Aficamten is a next-generation cardiac myosin inhibitor designed for once-daily dosing with a suitable projected human half-life. It reaches a steady state within two weeks and offers a broad therapeutic window in vivo, along with a well-defined pharmacokinetic/pharmacodynamic (PK/PD) relationship ^[1].

Aficamten shows moderate oral bioavailability following administration, with rates of 98% in mice, 55% to 79% in rats, 45% in dogs, and 41% in monkeys. These figures are based on doses of 1 mg/kg in mice, 2 mg/kg to 8 mg/kg in rats, 1 mg/kg in dogs, and 1 mg/kg in monkeys ^[1].

Aficamten demonstrates terminal elimination half-lives of 4.5 hours in mice, 3.0 hours in rats, 33.8 hours in dogs, and 8.1 hours in monkeys following intravenous administration at doses of 0.5 mg/kg in mice, 1 mg/kg in rats and dogs, and 1.0 mg/kg in monkeys ^[1].